NVST vs SYRE
Envista Holdings vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
NVST
Envista Holdings
76
Strong Buy
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
| Metric | NVST | SYRE |
|---|
| AI Score |
76
|
67
|
| Price |
$28.51
|
$102.72
|
| P/E Ratio |
48.34×
|
-52.69×
|
| ROE |
1.5%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
55.5%
|
0.0%
|
| Debt / Equity |
0.52×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.3
|
53.3
|
| Beta |
0.861
|
3.026
|
| Expected Upside |
+1.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVST versus SYRE.
NVST leads by 9 points.
NVST scores 76/100 (Strong Buy) versus SYRE at 67/100 (Insufficient Data).
NVST Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 14.2% downside vs 1.4% upside.
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical